BioSpace News Archive

The company’s head of drug development, Samit Hirawat, told analysts in a conference call last week that the decision was about working with the best drugs, particularly in a crowded field like BCMA.

An observational study published in the Proceedings of the National Academy of Sciences suggests there is a strong positive association between the number of coronavirus disease 2019 (COVID-19) aerosol droplets an individual breathes out with age, infection and body weight.

Immunai today announced it has received $60 million in Series A funding, bringing its total funding since inception in December 2018 to $80 million.

In the waning weeks of the fourth quarter of the 2020 fiscal year, AstraZeneca terminated several clinical programs, including some oncology and heart-related studies, as well as one COVID-19 related trial.

The U.S. FDA approved Regeneron’s monoclonal antibody Evkeeza (evinacumab-dgnb) as an add-on treatment for adult and pediatric patients ages 12 and above with homozygous familial hypercholesterolemia (HoFH).

DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced preclinical data evaluating the use of DNX-2401 against the pediatric brain malignancies atypical teratoid/rhabdoid tumor (AT/RT) and primitive neuroectodermal tumors (PNETs) was published in Clinical Cancer Research

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has committed to investing up to $25 million in minority-serving financial institutions.

ProterixBio, Inc. announced today commercial availability of a quantitative COVID-19 serology assay that has been validated for dried blood spots (DBS) from a finger stick. This is an update to the previously released SARS-CoV-2 (RBD) IgG Antibody test and is being offered as a testing service through ProterixBio’s high-complexity CLIA testing laboratory

The Thermo Scientific Dionex Easion and Thermo Scientific Dionex Aquion Ion Chromatography systems are now available to order online

Loki Therapeutics, an immuno-oncology company developing next-generation cancer therapeutics that leverage childhood vaccination recall antigens, announced its Chief Executive Officer Chris Bradley will present at the BIO CEO & Investor Digital Conference taking place February 16-18, 2021.